Hercules Capital (HTGC) amended its loan and security agreement with clinical‑stage biopharmaceutical company Savara Inc., adding up to $75 million of debt that will be released only after the U.S. Food and Drug Administration approves Savara’s investigational therapy MOLBREEVI.
The amendment does not include warrants and extends Savara’s balance sheet, providing a total of $150 million in non‑dilutive capital when combined with a prior $75 million royalty financing. The new facility is tied to a regulatory milestone, giving HTGC a contingent source of capital that could be deployed if the therapy receives approval.
For HTGC, the deal expands its loan portfolio and potential interest income. The milestone‑based structure aligns HTGC’s returns with Savara’s regulatory progress, reducing credit risk if the therapy is approved. The transaction also reinforces HTGC’s strategy of providing structured debt to high‑growth life‑science companies, and it demonstrates the firm’s ability to secure new originations in a competitive market.
For Savara, the additional debt boosts liquidity and supports the development and commercialization of MOLBREEVI. The combined $150 million of non‑dilutive capital extends the company’s runway and provides a financial cushion while the therapy moves through the FDA review process, which could conclude in Q3 2026 if priority review is granted.
The transaction comes after HTGC’s Q3 2025 earnings, in which the company reported earnings per share of $0.49 versus expectations of $0.48 and total investment income of $138.1 million. The earnings beat reflects strong loan performance and disciplined cost management, underscoring the firm’s robust financial position and its capacity to support additional debt facilities such as this one.
The deal illustrates the continued demand for venture‑debt financing in the life‑sciences sector and highlights HTGC’s role as a key lender to companies pursuing breakthrough therapies. By providing milestone‑contingent capital, HTGC positions itself to benefit from potential regulatory approvals while maintaining a diversified loan portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.